Welcome to our dedicated page for Tonix Pharmaceuticals Holding SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tonix Pharmaceuticals Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tonix Pharmaceuticals Holding's regulatory disclosures and financial reporting.
Tonix Pharmaceuticals Holding Corp. reported strong early commercialization of its CNS portfolio but continued heavy losses for the quarter ended June 30, 2026. Net product revenue was $13.5 million for the quarter and $20.4 million for the first half of 2026, up sharply from 2025, driven mainly by the U.S. launch of TONMYA for fibromyalgia and migraine products Zembrace SymTouch and Tosymra.
Operating expenses increased substantially as the company scaled commercial and R&D activities. For the first half of 2026, research and development expense was $37.6 million and selling, general and administrative expense was $64.6 million, leading to a net loss of $80.7 million for the six-month period. Cash used in operating activities was $84.6 million.
Tonix ended June 30, 2026 with $176.2 million in cash and cash equivalents, total assets of $254.1 million and working capital of approximately $172.6 million, supported by $53.6 million of ATM equity proceeds in the first half. Management expects existing cash plus subsequent equity raises to fund operations into early second quarter 2027, but not for 12 months from the financial statement issuance date, and disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. The company continues to advance a broad pipeline across CNS, infectious disease, immunology and rare diseases, including Phase 2 and preclinical programs.
Tonix Pharmaceuticals reported strong second quarter 2026 growth in commercial performance driven by TONMYA, its fibromyalgia treatment launched in November 2025. Net product revenue was $13.5 million for the quarter, up from $2.0 million a year earlier, including $11.0 million from TONMYA and $2.5 million from migraine products. TONMYA net sales increased approximately 197% quarter-over-quarter and total prescriptions reached 12,592, doubling versus the prior quarter, with refills up 207%.
Payer coverage expanded meaningfully, with TONMYA now reaching about 136 million covered lives (43% of U.S. covered lives) across commercial, managed Medicare, and Medicaid, expected to rise to roughly 145 million on January 1, 2027. Tonix is growing its TONMYA sales force to about 150 representatives by September 2026. The company continues to invest heavily in its pipeline, including Phase 2 programs for TNX-102 SL in major depressive disorder and adaptive Phase 2 planning for TNX-4800 in Lyme disease prevention. These initiatives contributed to a net loss of $40.6 million for the quarter and net cash used in operating activities of $84.6 million for the first half of 2026, funded by $176.2 million in cash and cash equivalents as of June 30, 2026 and additional ATM proceeds.
Tonix Pharmaceuticals Holding Corp. reported receiving official minutes from a Type C meeting with the U.S. FDA outlining alignment on an adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody to prevent Lyme disease in U.S. adults.
The planned randomized, placebo-controlled study would enroll approximately 3,300 adults in Lyme-endemic areas over two seasons, randomizing participants 1:1 to TNX-4800 450 mg subcutaneously or placebo in a two-dose regimen three months apart. The primary efficacy endpoint is Lyme disease prevention at six months after the first dose, with a key secondary endpoint at three months, and a primary safety objective of assessing safety and tolerability over 52 weeks.
Tonix plans to start the Phase 2 study in the first quarter of 2027 and expects most enrollment in 2028, with possible extension to 2029 if the attack rate is lower than expected. TNX-4800 is Fc-modified for extended half-life, is supported by non-human primate data showing high preventive efficacy, and is covered by a U.S. patent expiring in 2036, alongside potential 12-year biologic exclusivity.
Tonix Pharmaceuticals Holding Corp. reports an upcoming leadership change. On July 20, 2026, Dr. Gregory M. Sullivan informed the company that he will retire from his role as Chief Medical Officer, effective August 20, 2026. This reflects a planned transition in a key executive position.
Tonix Pharmaceuticals Holding Corp. entered into an agreement with a pharmacy benefit manager to provide TONMYA coverage for Medicare Part D beneficiaries, effective January 1, 2027. The agreement adds coverage for approximately 9 million Medicare lives, or 16% of about 55 million Medicare beneficiaries in the U.S.
Combined with two previously announced commercial coverage agreements and Medicaid availability in most states representing approximately 73 million lives, pharmacy coverage for TONMYA is expected to reach about 145 million covered lives on January 1, 2027, or 46% of 314 million covered lives. Tonix plans to expand its sales force by 50 representatives by mid–third quarter 2026, bringing the total to around 150 to support the product’s launch.
TONMYA, a 2.8 mg cyclobenzaprine HCl sublingual tablet, was approved by the FDA on August 15, 2025 for treatment of fibromyalgia in adults, with U.S. patent protection expected to provide market exclusivity until 2034. The disclosure also reiterates extensive safety, contraindication, and use-in-specific-populations information for TONMYA.
Tonix Pharmaceuticals Holding Corp. Chief Financial Officer Bradley Saenger reported a routine share acquisition through an employee stock plan. He obtained 1,453 shares of common stock at a price of $10.914 per share via the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan.
Following this transaction, Saenger directly holds 2,154 shares of Tonix common stock. The transaction is coded as “J” (other acquisition or disposition), reflecting a compensation-related, plan-based purchase rather than an open-market trade, so it carries limited signaling value about his view of the stock.
Tonix Pharmaceuticals Holding Corp. announced that the first patient has been enrolled in HORIZON, a potentially pivotal Phase 2 trial of TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder. The 6-week, randomized, double-blind, placebo-controlled study plans to enroll approximately 360 patients at about 30 U.S. sites, with a primary endpoint of change from baseline in the MADRS depression score at Week 6 and secondary measures including global impression, anxiety, and sleep quality. TNX-102 SL, a sublingual cyclobenzaprine tablet, is already FDA-approved as TONMYA for fibromyalgia in adults, and Tonix holds multiple U.S. patents expected to provide market exclusivity for TNX-102 SL until 2034, with method-of-use applications that could extend to 2044.
Tonix Pharmaceuticals Holding Corp. Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 890,366 shares of Common Stock, representing 5.6% of the class, with the cover date 06/09/2026.
A Joint Filing Agreement dated June 12, 2026 is attached; the filing lists the filers' principal address as 399 Park Avenue, New York.
Tonix Pharmaceuticals Holding Corp. director Carolyn E. Taylor reported an open-market purchase of common stock. She bought 1,415 shares of Tonix common stock at an average price of $10.55 per share. After this transaction, she directly owns 1,833 shares of Tonix common stock.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell reported an open-market purchase of 5,000 common shares. The shares were bought on June 8, 2026 at a weighted average price of $11.65 per share, with individual trade prices ranging from $11.63 to $11.65. Following this transaction, Stillwell directly holds 5,000 Tonix common shares.